Sensitivity of R clones to other types of anti-cancer molecules including genotoxic cytostatics (cisplatin, doxorubicin, bendamustine), targeted drugs (temsirolimus, bortezomib) or biological agents (monoclonal anti-CD20 antibody rituximab) remained unaffected, or was even augmented in the case of BTK inhibitor ibrutinib. Here, BTK is linked to cancer.